BioWorld

June 1, 2009

View Archived Issues

Celldex Extending Pipeline, Cash Runway in $95M CuraGen Deal

Celldex Therapeutics Inc. took another step toward expanding its pipeline, agreeing to buy CuraGen Corp. in a $94.5 million stock deal that will bring in 11 drug candidates and some added cash. (BioWorld Today) Read More

ASCO 2009 Kicks Off with Data in Hematologic Malignancies

Read More

Catalyst's Phase II Cocaine-Habit Failure Puts Squeeze on Finances

Read More

FDA Says Restrictive REMS Plan for Opioid Products Not Imminent

Read More

FDA Panel Backs Genmab's Arzerra in Refractory CLL

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Financings Roundup

Read More

Clinic Roundup

Read More